BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding BioCardia, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 20 | 22 | +2 |
| Shares | 3.10M | 2.87M | −228.7K (−7.4%) |
| Value | $12.3M | $9.01M | −$3.29M (−26.7%) |
New holders (6)
Institutions that held BioCardia, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Family Management Corp | 142,186 | $446.0K | 0.12% |
| Susquehanna International Group, LLP | 43,797 | $138.0K | 0.00% |
| State Street Corp | 21,000 | $66.0K | 0.00% |
| Commonwealth Equity Services, LLC | 16,492 | $51.0K | 0.00% |
| Millennium Management LLC | 10,015 | $31.0K | 0.00% |
| US Bancorp | 3,612 | $11.0K | 0.00% |
Sold out (4)
Institutions that held BioCardia, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Virtu Financial LLC | 33,264 | $132.0K |
| Marshall Wace, LLP | 21,680 | $86.0K |
| Magnus Financial Group LLC | 15,000 | $60.0K |
| UBS Group AG | 3,750 | $15.0K |